Roche had just finished buying the last public shares of Genentech in an attempt to procure their expertise in biotechnology. Use it for a multitude of other uses and Roche's major motives in the acquisition should happen to gain rights to Avastin. Positive clinical trials would have lead to significantly increased sales and growth other cancer applications. Rather, the negative results lead to Roche shares to fall by 10 percent. The episode raised questions at Roche about the efficacy of drug progress at the Genentech.
Phase III trial collapse corresponded to a considerable loss of time and money. And, in this case, the FDA annuled Avastin's acceptance for treatment of breast cancer causing additional harm to earnings opportunities for Roche. But, what was the appropriate resource allocation for early drug discovery and Phase II and III trials?
PUBLICATION DATE: January 06, 2012 PRODUCT #: MH0014-PDF-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
The Apple iPhone
Beth Israel Hospital Boston
Archdiocese of New York
Vick International Division: Tom McGuire
Assistant Professor Graham and Ms. Macomber (C)
Cumberland Metal Industries (A): Model Year 1978 Negotiations with Beta Motors
Generating Perceptual Maps from Social Media Data
Optimization and Expansion at OpenTable
International Marketing Plan
So what if remanufacturing cannibalizes my new product sales?
